Vaccines

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

With no approved nonsurgical options for plantar fibromatosis, Keenova's new study and late-stage trial offer a significant glimmer of hope for sufferers.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

A new online pharmacy is challenging the 'prescribe and forget' model for weight loss drugs, offering integrated clinical care to combat safety concerns.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

With a year of strong growth, key partnerships, and pipeline progress, all eyes are on ALK's upcoming annual results for 2025.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

With a new chair from Genmab and a board of industry titans, BioNJ is poised to bolster New Jersey's status as a global biotech powerhouse.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

Often dismissed as a simple stomach bug, norovirus is a serious threat. Health experts reveal why hand sanitizer fails and what you must do to stay safe.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.